
Keywords: BC; breast cancer; NAC; neoadjuvant chemotherapy; HER2; human epidermal growth factor 2; ER; oestrogen receptor; PR; progesterone receptor; TNBC; triple negative breast cancer; PET/CT; positron emission tomography computed tomography; pCR; pathologic comp